Admission Hyperglycemia is a Predictor of Mortality in Acute Heart Failure Patients without diabetes, but not in those with diabetes

Abstract

Background The impacts of admission hyperglycemia on clinical outcomes in non-DM patients with AHF have been poorly studied. The aim of this study, therefore, was to compare the impact of admission hyperglycemia on long-term clinical outcomes in AHF patients with or without DM. Methods A total of 5,625 patients (68.5 ± 14.5 years, 2,993 men; 53.2%) with acute decompensated heart failure enrolled in a nationwide AHF registry were divided into 2 groups; DM group (n = 2,152, 70.4 ± 11.4 years) vs. non-DM group (n = 3,473, 67.3 ± 16.0 years). Only AHF patients without history of DM and Hb A1c ≤6.4% were considered non-DM patients in this study. Patients in each group were further divided into 2 groups according to hyperglycemia (admission serum glucose level >200mg/dl): hyperglycemia group (n = 248) vs. no hyperglycemia group (n = 3,168) in non-DM; hyperglycemia group (n = 799) vs. no hyperglycemia group (n = 1326) in DM. All-cause death and rehospitalization during 1-year follow-up were compared. Results Death was developed in 970 patients (17.2%) and rehospitalization was developed in 2,533 patients (45.0%) during 1-year of follow-up. Kaplan-Meier survival analysis revealed higher all-cause mortality (p Conclusion Admission hyperglycemia was a significant predictor of 1-year clinical outcomes including mortality and rehospitalization in non-DM patients with AHF, but not in DM patients.